Upon completion of this workshop, the healthcare professional will be able to:
- Discuss the current recommendations against using T4 monotherapy for SCH due to lack of efficacy in most studies.
- Identify why the panel recommended against hormone therapy due to no important benefits of treatment and the possibility of harm.
- Review the studies demonstrating a low Free T3 level being responsible for symptomology and CVD.
- Review studies demonstrating improvement in symptoms with DTE as well as improvement in Free T3 levels with T3 and DTE, but not T4 monotherapy.
- Recall how combination therapy may be controversial but how physicians may prescribe it to improve adherence to treatment and patient well-being.
- Define the physiology behind lack of improvement with T4 monotherapy and the appropriate therapy to avoid the lack of efficacy of T4 monotherapy.
- Review the multiple studies demonstrating improvement in lipid parameters and a decrease in CIMT with thyroid administration.
- Evaluate the recommendations of recent authors and papers that subclinical hypothyroidism should not be treated. Lack of clinical benefit with thyroxine monotherapy and a lifelong burden of taking a medicine that does not work are discussed.
Neal Rouzier, MD
Enroll today with a Premium Membership for $495/year, for access to THIS course and:
- All 1 Hour Accredited Courses (28+ more added monthly)
- All upcoming Accredited Monthly Webinars
- All upcoming Journal Clubs AND Journal Club Library
- EBSCOhost – research articles for the BHRT Workshop Series and to support your own evidence based studies!
Are we given the articles referenced?
Of course – we pride ourselves in offering evidence-based courses. You’ll find the articles under Course Materials once you have enrolled.
Who is this course recommended for?
Anyone who is interested in learning more about BHRT!